4 th European Stroke Science Workshop

Transcription

1 4 th European Stroke Science Workshop P R O G R A M M E November 2017 Garmisch Partenkirchen, Germany Hotel Eibsee

2 Final Programme 4 th ESO Stroke Science Workshop / November 16 18, 2017 Garmisch-Partenkirchen, Germany, Hotel Eibsee Conference Chairs: Martin Dichgans (Munich), Stephanie Debette (Bordeaux), Daniel Strbian (Helsinki) Organizing Committee: Peter Rothwell (Oxford), Bart van der Worp (Utrecht), Joanna M. Wardlaw (Edinburgh), Angel Chamorro (Barcelona), Martin Dichgans (Munich), Stephanie Debette (Bordeaux), Daniel Strbian (Helsinki) THURSDAY, 16 NOVEMBER :00 Welcome address Martin Dichgans, Stephanie Debette, Daniel Strbian 18:10 Introduction keynote lecture: Gary Ford, Newcastle, United Kingdom 18:10 19:10 Keynote lecture: Improving the efficiency of clinical trial endpoints in stroke Craig Anderson, Sydney, Australia 19:40 Welcome Dinner FRIDAY, 17 NOVEMBER :00 8:00 Breakfast 8:00 9:45 Session I: Acute Stroke Treatment & Endovascular Therapy Convenor: Bart van der Worp, Utrecht, Netherlands Co-Chair: Urs Fischer, Berne, Switzerland 8:00 Opening remarks 8:05 Keynote lecture: Endovascular treatment: reperfusion failure and current challenges Carlos Molina, Barcelona, Spain 8:35 General discussion 8:40 1. Alternative thrombolytic agents Eivind Berge, Oslo, Norway

3 8:50 2. Nitroglycerin treatment in stroke Philip Bath, Nottingham, United Kingdom 9:00 3. Acute treatment of TIA and minor stroke Peter Kelly, Dublin, United Kingdom 9:10 4. Stroke outcomes measures, choice of clinical endpoints, and other challenges Ken Lees, Glasgow, United Kingdom 9:20 9:45 Open discussion 9:45 10:15 Coffee break 10:15 12:00 Session II: Small Vessel Disease Convenor: Joanna Wardlaw, Edinburgh, United Kingdom Co-Chair: Frank-Erik de Leeuw, Nijmegen, Netherlands 10:15 Opening remarks 10:20 Keynote lecture: Current mechanistic concepts Costantino Iadecola, New York, United States 10:50 General discussion 10:55 1. Novel risk factors for SVDs from early life effect size, mechanisms, and potential for modifiability Joanna Wardlaw, Edinburgh, United Kingdom 11:05 2. Cortical pathology in cerebral SVD Eric Jouvent, Paris, France 11:15 3. Novel biomarkers for SVD Marco Düring, Munich, Germany 11:25 4. Ultra-high field MRI Zooming into SVD Susanne van Veluw, Boston, United States 11:35 12:00 Open discussion 12:00 14:00 Lunch and time for recreational activities 14:00 15:45 Session III: Opportunities for stroke research in the omics area Convenor: Stephanie Debette, Bordeaux, France Co-Chair: Bo Norrving, Lund, Sweden 14:00 Opening remarks

4 14:05 Keynote lecture: Clinical applications of genetics to cardiovascular disease Nilesh Samani, Leicester, United Kingdom 14:35 General discussion 14:40 1. MEGASTROKE novel targets and clinical implications Martin Dichgans, Munich, Germany 14:50 2. Genetics of imaging-defined vascular phenotypes Stephanie Debette, Bordeaux, France 15:00 3. Epigenetics, Proteomics, Metabolomics: where is this taking us? David Tregouet, Paris, France 15:10 4. Mendelian stroke: novel genes, novel mechanisms Elisabeth Tournier-Lasserve, Paris, France 15:20 15:45 Open discussion 15:45 16:15 Coffee break 16:15 18:00 Session IV: Vascular cognitive impairment Convenor: Martin Dichgans, Munich, Germany Co-Chair: Geert Jan Biessels, Utrecht, Netherlands 16:15 Opening remarks 16:20 Keynote lecture: Multidomain interventions for dementia prevention Edo Richard, Amsterdam, Netherlands 16:50 General discussion 16:55 1. Vascular Prevention: Is there any hope after HOPE-3 Michael Brainin, Krems, Austria 17:05 2. Trajectories of vascular cognitive impairment Carole Dufouil, Bordeaux, France 17:15 3. Transient cognitive impairment: concept and clinical implications Terry Quinn, Glasgow, United Kingdom 17:25 4. Capillary pathways to stroke and cognitive decline Leif Ostergaard, Aarhus, Denmark 17:45 18:10 Open discussion 18:10 Adjourn

5 19:00 Special lecture: The Art and Psychology of Illusion Why our Brains fall for Deceptions Thomas Fraps, Munich, Germany 19:30 Banquette Dinner SATURDAY, 18 NOVEMBER :00 8:00 Breakfast 8:00 9:45 Session V: Intracerebral and subarachnoid haemorrhage Convenor: Gabriël Rinkel, Utrecht, Netherlands Co-Chair: Charlotte Cordonnier, Lille, France 8:00 Opening remarks 08:05 Keynote lecture: Blood pressure in acute ICH: do we need additional trials after INTERACT2 and ATTACH-II Thorsten Steiner, Frankfurt, Germany 8:35 General discussion 8:40 1. Interventional strategies for ICH: still an option? Jürgen Beck, Berne, Switzerland 8:50 2. ICH and statins: no need to worry? Hanne Krarup Christensen, Copenhagen, Denmark 9:00 3. Why don t we use antithrombotics regularly after ICH? Roland Veltkamp, London, United Kingdom 9:10 4. Paradigm shift in SAH: from macro- to microvasospasm Nick Plesnila, Munich, Germany 9:20 9:45 Open discussion 9:45 10:15 Coffee break 10:15 11:50 Session VI: Summarizing the evidence & alternative treatment concepts Convenor: Jean-Louis Mas, Paris, France Co-Chair: Valeria Caso, Perugia, Italy 10:15 Opening remarks

6 10:20 Keynote lecture: PFO closure time to close the discussion? Krassen Nedeltchev, Aarau, Switzerland 10:50 General discussion 10:55 1. Sensory stimulation - a novel paradigm for treating acute stroke? Jean-Claude Baron, Paris, France 11:05 2. Normobaric oxygen in acute stroke: dead or still alive? Christine Roffe, Newcastle, United Kingdom 11:15 3. Targeting brain oedema in stroke: preclinical and clinical data Daniel Strbian, Helsinki, Finland 11:25 4. ESO Guideline update George Ntaios, Larissa, Greece 11:35 11:50 Open discussion 11:50 13:00 Session VII: Neural Circuits, Recovery, and Rehabilitation Convenor: Daniel Strbian, Helsinki, Finland Co-Chair: Matthias Endres, Berlin, Germany 11:50 Keynote lecture: Non-invasive brain stimulation after stroke: Hope or hype? Christian Grefkes, Cologne, Germany 12:20 General discussion 12:25 1. Therapeutic network modulation by individualized non-invasive brain stimulation Ulf Ziemann, Tübingen, Germany 12:35 2. Functional integration of transplanted cells in neuronal circuits Sofia Grade, Munich, Germany 12:45 3. Stem Cell Therapy in Stroke: Fiction or Future Keith Muir, Glasgow, United Kingdom 12:55 4. Post-stroke aphasia: what can we offer after RATS3? Lonneke de Lau, Amsterdam, Netherlands 13:05 13:30 Open discussion 13:30 13:35 Farewell and close of meeting Stephanie Debette, Daniel Strbian & Martin Dichgans 13:35 14:15 Late lunch and departure

7 Notes

8